Prep for USMLEPrep for USMLE
         Forum      |     Resources New Posts   |   Register   |   Login


Post Reply  
  • 0/5
  • 1
  • 2
  • 3
  • 4
  • 5

Author9 Posts

A well-done randomized trial evaluated the efficacy of full-dose
subcutaneous low-molecular-weight heparin (LMWH) versus
warfarin (international normalized ratio [INR], 2.0-3.0) in
reducing recurrent venous thromboembolism (VTE) in a group
of patients with VTE and active cancer. The study duration was
6 months. During that time, 17% of the cancer patients receiving
warfarin had recurrent VTE compared with 9% of patients
receiving full-dose subcutaneous LMWH. On the basis of this
information, how many patients need to be treated for 6 months
with subcutaneous LMWH to prevent one additional VTE?

a. 17%
b. 12%
c. 9%
d. 8%
e. 4%




grin u have a passion for math, rkmehta

answer is B

You are asked to determine the number needed to treat (NNT) in
a randomized trial reporting that the LMWH-treated group had an
event rate of 9%. Therefore, the experimental event rate (EER) is 9%.

The warfarin-treated group had an EER of 17%. Therefore,
the control event rate (CER) is 17%.

NNT = 1/ARR, where ARR = (CER − EER). In this case, 17% − 9% = 8%.

Therefore, NNT = 1/.08 or about 12.


OOOPS....ITS 'one additional vte' i should improve my reading..sad

no passion for maths....old days r gone...iit ws in school days....sad


i hv a passion for USMLE...grin

when z ur xam avir??


it was, in March

now i read CS cases in the evening and try to maintain internal med fresh in the morninggrin


so u r helping us...smiling face keep it up...wats ur score in ck? i m sure >250...smiling face


sticking out tongue 93


bt its knowledge wat matters....wink

Bookmark and Share

Login or Register to post messages

show Similar forum topics

NNT, NNH, Attributable risk
show Related resources

Advertise | Support | Privacy | TOS | Premium | Contact